Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

INDIANAPOLIS (WISH) — A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose weight. While these drugs are becoming wildly ...

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes management. A search for NovoPen ® publications from 1985 onwards was ...

The global market for Generic Injectables was estimated at US$95.2 Billion in 2023 and is projected to reach US$206.8 Billion by 2030, growing at a CAGR of 11.7% from 2023 to 2030. This comprehensive ...

It was her research and development of Novo Nordisk's first daily GLP-1 shot for diabetes (liraglutide, approved in the US in 2010) that would spur the development of those more powerful ...

Specifically, she focused her research on injectable peptides ... her teams at Novo Nordisk invented an entirely new class of diabetes and weight loss drugs, she's still level-headed about ...